Dr Reddy’s Laboratories expects to satisfactorily perform despite forecasted volatile fiscal year

INDIA – Due to the onset of the corona virus pandemic globally, Dr. Reddy’s Laboratories expects its business growth to be volatile in the current fiscal year according to its financial report. The drug company also noted that despite this setback caused by various challenges within the market, they are optimistic to have a satisfactory performance owing to the fact that they have sufficient growth levers to deliver on its business growth. For the 2020-21 fiscal year, the company posted a consolidated net profit of Rs 1,952 crore (US$262.8M) against…

Read More

Dr. Reddy’s launches icosapent ethyl capsules into the U.S market

US – Dr. Reddy’s Laboratories Ltd, a leading multinational pharmaceutical company based in India and overseas, has launched its U.S. Food and Drug Administration (USFDA) approved 1-gram Icosapent ethyl capsules. The drug was approved as a diet supplementary to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia, a condition associated with high amounts of fatty molecules(triglyceride) in the blood and can result to a patient having skin lesions. Icosapent ethyl capsule approval and launch was timely at a time when hypertriglyceridemia and its related complications are becoming a…

Read More